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Available online 26 July 2016Epidemiological studies revealed an association between type-1 diabetes (T1D) and schizophrenia but the ﬁnd-
ings reported to date have been controversial. To clarify the inconsistency across studies, T1D-associated autoan-
tibodies were examined in plasma samples collected from 272 patients with schizophrenia and 276 control
subjects. An in-house enzyme-linked immunosorbent assay (ELISA) was developed using three linear peptide
antigens, one of which was derived from glutamic acid decarboxylase (GAD) and two were derived from
insulinoma-associated antigen 2 (IA2). Mann-Whitney U test showed a signiﬁcant decrease in the levels of plas-
ma IgG against the IA2b antigen in schizophrenia patients as compared to control subjects (Z = −3.54, p =
0.0007), while no signiﬁcant difference was found between these two groups either in anti-IA2a IgG levels
(Z =−1.62, p = 0.105) or in anti-GAD IgG levels (Z =−1.63, p = 0.104). Linear regression analysis indicated
no association of antipsychotic medication with the levels of plasma IgG against IA2a, IA2b or GAD, while the
levels of plasma IgG for these 3 peptide antigens were signiﬁcantly correlatedwith each other. Binary logistic re-
gression showed that neither the DQ2.5 variant nor the DQ8 variant was associated with circulating levels of 3
T1D-associated autoantibodies in both the patient group and the control group. The coefﬁcient of variation
was 10.7% for anti-IA2a IgG assay, 10.1% for anti-IA2b IgG assay and 10.7% for anti-GAD IgG assay. The present
work suggests that T1D-associated antibodies are unlikely to confer risk of schizophrenia and that the in-
house ELISA developed with linear peptide antigens is highly reproducible.






Schizophrenia is a severe psychiatric disorder with an incidence rate
of 0.7% in the population worldwide (Saha et al., 2005). It is a complex
heterogeneous disorder that presents clinically with positive symptoms
(such as hallucinations and delusions), negative symptoms (such as ap-
athy and social withdrawal) and cognitive impairments (such as work-
ingmemory loss). The etiology of schizophrenia is complex and as yet is
still unclear, although it is known to be a highly heritable disorder with
inheritability of up to 81% (Sullivan et al., 2003). A multi-stage schizo-
phrenia genome-wide association (GWA) study conﬁrmed that 108
loci in the human genome were involved in genetic risk of the disease
(Schizophrenia Working Group of the Psychiatric Genomics
Consortium, 2014), suggesting that schizophrenia is a polygenic disor-
der with a heterogeneous pattern. This GWA study also showed that
the strongest association signal was identiﬁed in the human major his-
tocompatibility complex (MHC), also known as the human leukocyte
antigen (HLA) locus in the short arm of chromosome 6 (p =
3.48 × 10−31); enrichment analysis revealed that most of theseUniversity of theHighlands and
ess IV2 3JH, UK.
. This is an open access article undersusceptibility genes were highly expressed in both human brain and
B-lymphocytes, indicating an important role in immunity.
The HLA region is highly polymorphic and contains N100 genes es-
sential for the regulation of immune function; it is also involved in pre-
disposition to a number of human diseases such as inﬂammatory
diseases and autoimmune disorders. Type-1 diabetes (T1D) is an auto-
immune disease mainly caused by autoimmune destruction of pancre-
atic β-cells, leading to the failure of producing insulin for glucose
metabolism. Several epidemiological studies suggested that T1Dwas as-
sociatedwith schizophrenia but theﬁndings reported to date have been
controversial. Eaton et al. (2006) reported a lower prevalence of T1D in
patients with schizophrenia than control subjects; Juvonen et al. (2007)
reported a decreased incidence of schizophrenia in patients with T1D.
Conversely, a couple of studies reported an increase in T1D prevalence
among patients with schizophrenia, with a relative risk/odds ratio of
1.27 and 1.54, respectively (Benros et al., 2011; Chen et al., 2012). In ad-
dition, the HLA class II (HLA-II) alleles coding for DQ8 and DQ2.5 mole-
cules account for up to 50% of genetic risk of T1D (Todd, 2010; Steck and
Rewers, 2011) and over 60% T1D patients carry DQ2/DQ8 genotypes
(Eringsmark Regnéll and Lernmark, 2013). However, GWA studies
have conﬁrmed that the frequencies of DQA1*0501 andDQB1*0201 var-
iants coding for DQ2.5 molecule are signiﬁcantly lower in patients with
schizophrenia than control subjects (International Schizophreniathe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 3
Kolmogorov-Smirnov test for normal distribution of circulating antibody levels.
Antibody Skewness Kurtosis D statistic p
Patient
IA2a 1.3 2.18 0.12 b0.0001
IA2b 1.7 5.70 0.11 b0.0001
GAD 1.1 1.68 0.11 b0.0001
Control
IA2a 1.9 4.73 0.14 b0.0001
IA2b 1.3 2.02 0.12 b0.0001
GAD 1.7 4.65 0.10 b0.0001
Table 1





187P. Hallford et al. / Schizophrenia Research 176 (2016) 186–190Consortium, 2009; Sekar et al., 2016), and in a recent studywe have also
found no association of the DQ8 variant with schizophrenia in a Scottish
population (unpublished data). Therefore, schizophrenia and T1D are
unlikely to share the same genetic risk determined at the HLA-II locus.
To clarify the inconsistency between epidemiological studies, it is
useful to examine the prevalence of T1D-associated autoantibodies in
schizophrenia. More than ﬁve distinct T1D-associated autoantigens
have been identiﬁed for autoimmune responses in T1D, including insu-
lin, glutamic acid decarboxylase (GAD), insulinoma-associated antigen
2 (IA2), zinc transporter 8 (ZnT8) and islet cell antigens (ICAs). Both
GAD and IA2 are involved in function of the central nervous system
and the neuroendocrine system (Nishida et al., 2009; Davis et al.,
2016). GAD is an enzyme that catalyzes the decarboxylation of gluta-
mate to ɤ-aminobutyric acid (GABA), the major inhibitory neurotrans-
mitter in adult mammalian brain, which plays a major role in the
development of normal brain and has been strongly implicated in the
pathobiology of schizophrenia (Wassef et al., 2003; Straub et al., 2007;
Taylor and Tso, 2015). IA2 has been found to be highly expressed in
the pituitary gland (Nishida et al., 2009). A few studies have been per-
formed to examine autoantibodies against GAD and IA2 in schizophre-
nia but failed to show a signiﬁcant change (Cohen et al., 2005;
Yarlagadda et al., 2008; Ezeoke et al., 2013). Because the sample size
used in the above studies was rather small, it is particularly important
to replicate such initial work in a large sample size. This study was
thus undertaken to develop an in-house enzyme-linked immunosor-
bent assay (ELISA) using linear peptide antigens derived from GAD
and IA2, and to analyse the levels of autoantibodies against these pep-
tide antigens in plasma samples from schizophrenia patients and con-
trol subjects.
2. Materials and methods
2.1. Subjects
A total of 548 archived plasma samples collected from patients with
schizophrenia (n = 272, 192 males and 80 females, mean age 44.7 ±
12.1 years) and control subjects (n = 276, 208 males and 68 females,
mean age 41.9 ± 13.0 years), were used to examine circulating levels
of IgG antibodies against GAD and IA2. These case-control samples
were collected through the University of Aberdeen in the period be-
tween 2003 and 2008. All the subjects were classiﬁed as British Cauca-
sian, including English, Scottish, Welsh and Irish individuals. All
patients were diagnosed as having schizophrenia based on the DSM-Table 2
Antipsychotic drugs used by schizophrenia patients at the time of sampling.
Medication Patient (n) Percentage of all cases (%) Male (n) Age (years)a
Amisulpride 9 3.3 6 38.6 ± 11.1
Clozapine 48 17.6 36 34.1 ± 9.9
Haloperidol 1 0.04 0 46.0
Olanzapine 32 11.8 22 41.7 ± 13.8
Phenothiazine 15 5.5 8 50.1 ± 9.1
Quetiapine 8 2.9 7 33.0 ± 12.0
Risperidone 18 6.6 11 53.3 ± 13.0
Sulpiride 3 1.1 2 52.4 ± 17.2
Thioxanthine 37 13.6 24 46.2 ± 11.0
N1 drug 31 11.4 23 40.2 ± 11.6
Unknown 70 25.7 52 42.0 ± 12.4
a Mean± SD.IV criteria and control subjects were screened for psychiatric disorders
as mentioned in previous GWA study (International Schizophrenia
Consortium, 2009). Antipsychotic drugs used by schizophrenia patients
at the time of sampling are listed in Table 2; of these 272 patients, 171
were taking a single antipsychotic drug, 31 were taking more than one
drug and 70 failed to give medication details. All subjects gave written
informed consent to giving blood samples for study of the pathogenesis
of schizophrenia. This study was approved by a local ethics committee
and conformed to the Declaration of Helsinki.
2.2. Detection of plasma IgG
Three linear peptide antigens were applied to develop an in-house
ELISA, one derived from GAD and two derived from IA2; their amino
acid sequences are given in Table 1, of which IA2a was designed based
on the computational prediction of HLA-II epitopes (Söllner et al.,
2010;Wang et al., 2010), IA2b based on epitope LGPEGAHGDTTFEYQDL
sequence that was conﬁrmed to be involved in the autoimmune re-
sponses in patients with T1D (http://www.pepperprint.com/), and
GAD based on the epitope information for human autoimmune disease
in the Immune Epitope Database (http://www.iedb.org/). In brief,
Maleimide-activated plates (Cat. 15150, Thermo Scientiﬁc, Edinburgh,
UK) were coated based on the Manufacturer's instruction. The anti-
gen-coated plate was washed twice with 200 μl Wash Buffer that was
phosphate-buffered saline (PBS) (P4417, Sigma-Aldrich, Ayrshire, UK)
containing 0.05% Tween-20; 50 μl plasma sample diluted 1:200 in
Assay Buffer that was PBS containing 0.5% bovine serum albumin
(BSA) was then added to each sample well; 50 μl Assay Buffer was
added to each negative control (NC) well and 50 μl positive control
(PC) sample was added to each PC well. Following incubation at room
temperature for 1.5 h, the plate was washed three times with 200 μl
Wash Buffer and 50 μl peroxidase-conjugated goat anti-human IgG an-
tibody (ab98567, Abcam, Cambridge, UK) diluted 1:30000 in Assay
Buffer was added to each well. After incubation at room temperature
for 1 h, colour development was initiated by adding 50 μl Stabilized
Chromogen (SB02, Life Technologies, Warrington, UK) and terminated
after 20 min by adding 25 μl Stop Solution (SS04, Life Technologies,
UK). The measurement of optical density (OD) was completed on a mi-
croplate readerwithin 10min at 450 nmwith a referencewavelength of
620 nm. All the samples were tested in duplicate and the speciﬁc bind-
ing ratio (SBR) was used to represent the relative levels of plasma IgG
antibodies. Calculation of SBR is as follows:
SBR ¼ ODSample–ODNC
 
= ODPC–ODNCð ÞTable 4
Inter-assay deviation between ELISA-testing plates.
Antigen Number of plates Mean ± SDa CV (%)
IA2a 41 0.794 ± 0.085 10.7
IA2b 41 0.636 ± 0.064 10.1
GAD 43 0.747 ± 0.080 10.7
a Antibody levels were expressed in SBR.
Table 7
Association between the DQ2.5 variants and circulating IgG against IA2 and GAD antigens.
Subjects Antigen Log-likelihood G2 statistic pa
Patient
IA2a 1.331 2.66 0.103
IA2b 3.44 0.086
GAD 1.722 3.44 0.086
Control
IA2a 0.197 0.39 0.530
IA2b 0.011 0.02 0.885
GAD 0.275 0.55 0.459
a The p-value of b0.017 was set for rejection of null hypothesis.
Table 5









Male 192.7 (192) 207.8 (208) −1.31 0.192
Female 71.6 (80) 78.3 (68) −1.00 0.317
Combined 263.5 (272) 285.4 (276) −1.62 0.105
IA2b
Male 180.5 (192) 219.0 (208) −3.32 0.001
Female 69.6 (80) 80.3 (68) −1.52 0.130
Combined 250.4 (272) 298.3 (276) −3.54 0.0007
GAD
Male 188.2 (192) 211.9 (208) −2.05 0.04
Female 75.3 (80) 73.5 (68) 0.26 0.797
Combined 263.4 (272) 285.4 (276) −1.63 0.104
a Mann-Whitney U test; p-value of b0.017 set for rejection of null hypothesis.
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tween duplicated OD values of each sample to their sumwas used to as-
sess the precision for the in-house ELISA antibody test. If the ratio was
found to be N10%, the test of this sample was treated as invalid and
was not used for data analysis.2.3. Genotyping of the DQ2/DQ8 variants
HLA-tagging single nucleotide polymorphisms (SNPs) rs2187668
and rs7454108 were used to genotype the alleles coding for DQ2.5
and DQ8 molecules using a TaqMan protocol, in which rs2187668
minor allele “A” represents the DQA1*0501 ~ DQB1*0201 haplotype
(DQ2.5) and rs7454108 minor allele “G” represents the
DQA1*0301 ~ DQB1*0302 haplotype (DQ8) in the European Caucasian
population (Monsuur et al., 2008). TaqMan genotyping reagents were
supplied by Applied Biosystem (Paisley, UK). The OneStep real-time
PCR system (Applied Biosystems) was used to amplify DNA samples
for genotyping of rs2187668 and rs7454108; genotype calls wereTable 6
Association between antipsychotic medication and circulating IgG against IA2 and GAD
antigens.
Drug Regression IA2a IA2b GAD
Amisulpride
Adj r2 −0.009 0.010 0.012
t 0.269 0.062 0.861
p 0.768 0.950 0.390
Clozapine
Adj r2 −0.009 0.021 0.012
t 0.280 −1.770 −0.900
p 0.779 0.078 0.369
Haloperidol
Adj r2 −0.009 0.012 0.013
t 0.288 0.826 0.908
p 0.773 0.409 0.365
Olanzapine
Adj r2 −0.008 0.017 0.020
t 0.707 1.436 1.657
p 0.480 0.152 0.099
Phenothiazine
Adj r2 −0.010 0.013 0.009
t 0.039 0.926 −0.059
p 0.969 0.355 0.953
Quetiapine
Adj r2 −0.006 0.012 0.010
t −0.925 −0.734 −0.441
p 0.356 0.464 0.659
Risperidone
Adj r2 −0.010 0.010 0.016
t 0.277 −0.507 −1.384
p 0.782 0.613 0.168
Sulpiride
Adj r2 0.010 0.011 0.023
t −0.087 0.550 1.893
p 0.930 0.583 0.059
Thioxanthine
Adj r2 −0.009 0.018 0.015
t 0.393 1.518 1.215
p 0.694 0.130 0.226
Adj r2, adjusted r2 for sex and age.made manually based on the distribution of three clusters resulting
from plotting the ampliﬁcation of allele 1 versus allele 2.2.4. Data analysis
Kolmogorov-Smirnov test was applied to test the distribution of an-
tibodies levels in both the patient group and the control group. Because
circulating levels of IgG antibodies against 3 antigens all failed to show a
normal distribution (Table 3),Mann-WhitneyU testwas then applied to
examine the difference in SBR between the patient group and the con-
trol group. The p-value of b0.017was set for rejection of null hypothesis
as 3 antigens were tested in this study. The coefﬁcient of variation (CV)
was used to represent an inter-assay deviation estimated using pooled
plasma samples, namely quality control (QC) sample, which were ran-
domly collected from N20 healthy subjects and tested on every 96-
well plate. Linear regressionwas applied to examinewhich antipsychot-
ic drugs might affect the secretion of plasma antibodies speciﬁc for the
above 3 antigens. In such analysis, the antibody levelswere used as a de-
pendent variable, and medication, age and sex were used as the inde-
pendent variables. Binary logistic regression was applied to examine if
DQ2.5 and DQ8 were associated with altered levels of plasma IgG anti-
bodies against these 3 antigens.3. Results
The CV estimated based on the SBR from the QC sample was 10.7%
for anti-IA2a IgG assay, 10.1% for anti-IA2b IgG assay and 10.7% for
anti-GAD IgG assay (Table 4), suggesting that the in-house ELISA devel-
oped with linear peptide antigens was highly reproducible.
Mann-WhitneyU test revealed a signiﬁcant decrease in plasma anti-
IA2b IgG levels in the patient group when compared to the control
group (Z =−3.54, p = 0.0007), and male patients mainly contributed
to the decrease in anti-IA2b IgG levels (Table 5); there was no signiﬁ-
cant difference found between these two groups either in anti-IA2a
levels (Z =−1.62, p = 0.105) or in anti-GAD IgG levels (Z =−1.63,
p=0.104). Linear regression analysis showed no association of antipsy-
chotic medication with the levels of plasma IgG against IA2a, IA2b or
GAD (Table 6). Binary logistic analysis showed that neither the DQ2.5
variant nor the DQ8 variant was associated with circulating levels of
IgG antibodies against these 3 antigens in both the patient group and
control group (Tables 7 and 8).Table 8
Association between the DQ8 variants and circulating IgG against IA2 and GAD antigens.
Subjects Antigen Log-likelihood G2 statistic pa
Patient
IA2a 2.217 4.43 0.035
IA2b 0.095 0.19 0.663
GAD 0.889 1.78 0.182
Control
IA2a 0.203 0.41 0.524
IA2b 0.001 0.01 0.909
GAD 0.0005 0.00 0.976
a The p-value of b0.017 was set for rejection of null hypothesis.
Fig. 1. The correlation between circulating levels of IgG antibodies against linear peptide antigens derived fromGAD and IA2. a. IA2a vs IA2b: r=0.591, df=547, p b 0.001; b. IA2a vs GAD:
r = 0.480, df = 547, p b 0.001; c. IA2b vs GAD: r = 0.663, df = 547, p b 0.001.
189P. Hallford et al. / Schizophrenia Research 176 (2016) 186–190As shown in Fig. 1, correlation analysis demonstrated that circulating
levels of IgG antibodies against IA2a, IA2b and GAD were signiﬁcantly
correlated with each other, including anti-IA2a IgG vs anti-IA2b IgG
(r = 0.591, df = 547, p b 0.001), anti-IA2a IgG vs anti-GAD IgG (r =
0.480, df = 547, p b 0.001) and anti-IA2b IgG vs anti-GAD IgG (r =
0.663, df = 547, p b 0.001).
4. Discussion
Epidemiological studies that look at the link between T1D and
schizophrenia so far have been inconsistent. The question that the epi-
demiological data pose is whether T1D is a risk factor for schizophrenia
or is protective against the development of schizophrenia. The results
from this study suggest that T1D-associated antibodies are unlikely to
confer a risk of developing schizophrenia in the Caucasian population.
Of these three peptide antigens derived from GAD and IA2 (Table 1),
two failed to show immunogenic stimulation of T1D-associated anti-
body secretion, and the IA2b antigen might induce immune tolerance
to its self in patients with schizophrenia (Table 5). While the IA2b anti-
gen is not aHLA-DQ2/DQ8 restricted antigen based on the computation-
al prediction of HLA-II epitopes (Söllner et al., 2010;Wang et al., 2010),
it carries the LGPEGAHGDTTFEYQDL sequence that has been conﬁrmed
to be involved in the autoimmune responses in patients with T1D
(http://www.pepperprint.com/). The present work also showed that
neither the DQ2.5 variant nor the DQ8 variant was associated with
anti-IA2 and anti-GAD IgG antibodies (Tables 7 and 8). These observa-
tions suggest that both DQ8 and DQ2.5 molecules may present peptide
antigens from the environment rather than T1D-associated
autoantigens (Eringsmark Regnéll and Lernmark, 2013). It has been
demonstrated that early exposure to complex dietary proteins like
cow's milk could increase the risk of beta-cell autoimmunity in the
DQ2.5/DQ8 carriers and milk formula of casein hydrolysate could re-
duce such a risk (Knip et al., 2010).
It is worth noting that family history of T1Dhas been consistently re-
ported to be a risk factor for schizophrenia. Wright and colleagues re-
ported a signiﬁcant excess of T1D in the ﬁrst-degree relatives of
schizophrenia patients, especially in mothers (Wright et al., 1996);
Eaton et al. (2006) showed an incidence rate ratio of 1.5 for T1D preva-
lence in parents of schizophrenia patients, relative to parents of com-
parison subjects; Benros et al. (2012) demonstrated that the
individuals with T1D family history had relative risk of 1.3 to develop
schizophrenia. Because the role of T1D family history in enhancing
risk of schizophrenia may not be related to the HLA-DQ2.5/DQ8 geno-
types based on genetic analysis of schizophrenia as mentioned above,
maternal issue should be taken into account. Analysis of IgG antibodies
in cord blood samples revealed that maternal IgG antibodies to infec-
tious agents andwheat gluten could confer risk of non-affective psycho-
ses such as schizophrenia and autism (Blomström et al., 2012; Karlssonet al., 2012) as maternal IgG can cross the placenta. Accordingly, we hy-
pothesize that the mechanism behind the involvement of T1D family
history in schizophrenia risk may be due to maternal T1D-associated
IgG autoantibodies. It has been found that approximately 3% of infants
of non-diabetes mothers are positive for T1D-associated autoantibodies
in their cord blood samples (Hämäläinen et al., 2002). Therefore, there
is an urgent need to establish the link between T1D-associated autoan-
tibodies and schizophrenia.
Whilemale patients signiﬁcantly contributed to decreased anti-IA2b
IgG levels, gender does not appear to serve as a confounding factor for
antibody production as female patients also showed a decrease in
anti-IA2b IgG levels that did not achieve statistical signiﬁcance due to
small sample size (Table 5). Linear regression analysis showed no asso-
ciation of antipsychoticmedicationwith the levels of plasma IgG against
IA2a, IA2b or GAD, but this analysis is limited by the absence of drug-
free or naïve patients and incomplete medication histories. In conclu-
sion, T1D may have a complicated relationship with schizophrenia
and it is unlikely to confer risk of schizophrenia although maternal
T1D-associated autoantibodies may be a risk factor for the disease. In
addition, the in-house ELISA developed with linear peptide antigens in
this study is highly reproducible and may be useful for large-scale
screening of T1D-associated autoantibodies in the population.
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